BIO-Europe is the perfect time to start a conversation about your CRISPR license. We are excited to connect with companies who can benefit from this game-changing technology.
A meeting or a call with us is worthwhile for you if:
You are interested in possible use of CRISPR/Cas9 for internal research programs:
– Are you using modified cells or animals from an academic source?
– Are you generating in-house reagents?
You are interested in use of genetically modified cells in manufacturing. Including…
– mAbs
– Gene or cell therapy
– Vectors
– Industrial enyzmes or intermediates
You provide any services which utilize CRISPR/Cas9 or cells or animals modified by the technology. Including…
– High-throughput screening
– Target identification, Target validation
– Cell line development
– Disease specific cell models
– Animal models of disease
You have an interest in animal health applications. Including…
– Disease resistance, Vaccines Trait improvements
‘Your journey with CRISPR begins with a license from ERS Genomics. I am delighted to be back at BIO 2023. If you would like to learn more about CRISPR/Cas9 and licensing, connect with me and let’s talk.’
Explore more news on CRISPR/Cas9 and how it can provide a leading edge in the highly competitive biotech sector.
Here are the 5 key facts you need to know, so you can secure the licenses that will protect your product and your company.
Read Full ArticleIn The Medicine Maker, ERS Genomics CEO, Eric Rhodes explores the power and flexibility of CRISPR/Cas9 for the antibody manufacturing pipeline, including for next-generation antibody-drug conjugates to treat cancer. If antibody manufacturers are to meet the demand for these next-generation treatments, now is the time to embrace CRISPR gene editing..
Read Full ArticleDublin, Ireland, January 5, 2023: ERS Genomics announced that its first Canadian patent, CA 2872241, with broad claims to compositions and methods of using CRISPR/Cas9 in humans, animals, plants, and microbes has been granted to the CVC group. CVC stands for University of California, University of Vienna, and Emmanuelle Charpentier.
Read Full Article